232 results on '"Iacobelli, Massimo"'
Search Results
2. Use of defibrotide in COVID-19 pneumonia: comparison of a phase II study and a matched real-world cohort control
3. Progress in the contemporary management of hemophilia: The new issue of patient aging
4. Defibrotide for Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome: Interim Results from a Treatment IND Study
5. Supplementary Data from Preclinical Studies in Support of Defibrotide for the Treatment of Multiple Myeloma and Other Neoplasias
6. Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease: Final Results From the International Compassionate-Use Program
7. Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure
8. USP Potency Adjusted Bovine Mucosal Heparins are Comparable to Porcine Mucosal Heparin and May be Interchangeable for Anticoagulation
9. Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial
10. Use of Defibrotide in Patients with COVID-19 Pneumonia; Results of the Defi-VID19 Phase 2 Trial
11. Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease and Multiorgan Failure after Stem Cell Transplantation: A Multicenter, Randomized, Dose-Finding Trial
12. Hepatic Veno-Occlusive Disease following Stem Cell Transplantation: Incidence, Clinical Course, and Outcome
13. In vivo skin penetration, radical protection and structural changes after topical application of a herbal oil cream compared to topical calcipotriol in mild to moderate psoriasis
14. Endothelial dysfunction and its critical role in COVID‐19‐associated coagulopathy: Defibrotide as an endothelium‐protective, targeted therapy
15. Defibrotide: potential for treating endothelial dysfunction related to viral and post-infectious syndromes
16. Response to Maccio et al, “Multifactorial pathogenesis of COVID‐19‐related coagulopathy: Can defibrotide have a role in the early phases of coagulation disorders?”
17. Angiogenesis alteration by defibrotide: implications for its mechanism of action in severe hepatic veno-occlusive disease
18. Drug Safety Information Through the Internet: The Experience of an Italian Website
19. COVID‐19‐induced endotheliitis: emerging evidence and possible therapeutic strategies
20. Defibrotide for the Treatment of Endotheliitis Complicating Sars-Cov-2 Infection: Rationale and Ongoing Studies As Part of the International Defacovid Study Group
21. P1186PRELIMINARY RESULTS OF THE FIRST PHASE II CLINICAL TRIAL ON THE USE OF AN INNOVATIVE GLUCOSE-SPARING PD SOLUTION (FIRST)
22. P1136STUDY DESIGN OF ELIXIR, A MULTICENTER EUROPEAN PHASE III CLINICAL TRIAL AIMED TO TEST A GLUCOSE-SPARING PD SOLUTION WHERE GLUCOSE IS MOSTLY REPLACED WITH OSMO-METABOLIC AGENTS
23. Response to the Letter to the Editor by Eshghi P et al
24. A Meta-Analysis Evaluating the Risk of Bleeding-Related Adverse Events with Defibrotide Treatment
25. A Meta-Analysis Evaluating the Incidence of Bleeding Events With Intravenous Defibrotide Treatment Outside the Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome Setting
26. A Meta-Analysis Evaluating the Risk of Bleeding-Related Adverse Events with Defibrotide Treatment
27. A Generic Recombinant Factor VIIa is Comparable to the Branded Novoseven in In‐Vitro and Pharmacokinetic Studies in Primates
28. The use of defibrotide in blood and marrow transplantation
29. Final results from a defibrotide treatment-IND study for patients with hepatic veno-occlusive disease/sinusoidal obstruction syndrome
30. Rationale and design of ELIXIR, a randomized, controlled trial to evaluate efficacy and safety of XyloCore, a glucose-sparing solution for peritoneal dialysis
31. Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease
32. Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease: Final Results From the International Compassionate-Use Program
33. Recombinant Factor VIIa–Mediated Activation of Prothrombin Complex Concentrates
34. Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome with Multi-Organ Dysfunction: Final Results from a Pivotal, Historically Controlled, Phase 3 Trial
35. Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome with Multi-Organ Dysfunction: Final Results from a Pivotal, Historically Controlled, Phase 3 Trial
36. Recombinant Factor VIIa–Mediated Activation of Prothrombin Complex Concentrates.
37. Valutazione dell'uso e della sicurezza dei farmaci: esperienze in Italia
38. Risk factors and severe outcome in thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation
39. Defibrotide Interferes With Several Steps of the Coagulation-Inflammation Cycle and Exhibits Therapeutic Potential to Treat Severe Malaria
40. Regulatory T Cells Enhance the Allogeneic Activity of Endothelial-Specific Cytotoxic T Lymphocytes – Protective Effect of Defibrotide
41. Meta-Analysis of Defibrotide (DF) In the Treatment of Severe Hepatic Veno-Occlusive Disease (VOD) with Multi-Organ Failure (MOF) with Comparison to a Historical Control (HC).
42. The fibrinolytic mechanism of defibrotide: effect of defibrotide on plasmin activity
43. Defibrotide (DF) for the Prevention of Hepatic Veno-Occlusive Disease (VOD) in Pediatric Stem Cell Transplantion: Results of a Prospective Phase II/III Randomized, Multicenter Study.
44. Prolonged Administration of Defibrotide Is Non-Immunogenic in Rats and Dogs.
45. Defibrotide (DF) in the Treatment of Severe Hepatic Veno-Occlusive Disease (VOD) with Multi-Organ Failure (MOF) Following Stem Cell Transplantation (SCT): Results of a Phase 3 Study Utilizing a Historical Control.
46. Preclinical Studies in Support of Defibrotide for the Treatment of Multiple Myeloma and Other Neoplasias
47. Defibrotide Augments the Anticoagulant Actions of Heparin and Low Molecular Weight Heparins
48. Pharmacokinetics of Defibrotide in Non‐Human Primates is Dose Dependent.
49. Defibrotide for the Treatment of Veno-Occlusive Disease Post SCT: Preliminary Results of EU Compassionate Use Program in 332 Patients Confirm Promising Activity and Manageable Toxicity.
50. Reduced Fibrinolysis in the Hepatic Venous Occlusive Disease: Effect of Defibrotide on Plasmin Activity.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.